Mode of action studies for a novel anti-leishmania compound

ABSTRACT: We describe the development of a novel anti-leishmanial drug-like chemical series based on a pyrazolopyrimidine scaffold. The leading compound is efficacious in a mouse model of visceral leishmaniasis, and has suitable physicochemical, pharmacokinetic and toxicological properties for further development and has been declared a preclinical candidate. Detailed mode of action studies indicate that compounds from this series act principally by inhibiting the parasite protein kinases.

INSTRUMENT(S):

ORGANISM(S): Leishmania Donovani

DISEASE(S): Visceral Leishmaniasis

SUBMITTER: Michael Urbaniak  

LAB HEAD: Ian H Gilbert

PROVIDER: PXD009711 | Pride | 2018-11-30

REPOSITORIES: Pride